Loading patent…
AssigneeMonogram Biosciences, Inc.
InventorsNeil T. Parkin, Ellen Paxinos, Colombe Chappey, Mary T. Wrin, Andrea Gamarnik, Christos J. Petropoulos
Estimating the term…
The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.
A method for determining whether a HIV-1 has an increased likelihood of being hypersusceptible to treatment with a protease inhibitor, comprising:
A method for determining whether an individual infected with HIV-1 has an increased likelihood of being hypersusceptible to treatment with a protease inhibitor, comprising detecting, in a sample from said individual, the presence or absence of a mutation associated with hypersusceptibility to treatment with said protease inhibitor at amino acid position 16, 20, 33, 36, 37, 39, 45, 65, 69, 77, 89 or 93 of the amino acid sequence of the protease of the HIV-1, wherein the presence of said mutation indicates that the individual has an increased likelihood of being hypersusceptible to treatment with the protease inhibitor, with the proviso that said mutation is not L33F.
An isolated oligonucleotide between about 10 and about 40 nucleotides long encoding a portion of an HIV protease that comprises a mutation at amino acid position 16, 20, 33, 36, 37, 39, 45, 65, 69, 77, 89 or 93 of an amino acid sequence of said protease in said human immunodeficiency virus, wherein the mutation is associated with hypersusceptibility to a protease inhibitor, with the proviso that said mutation is not L33F.
A method for determining whether a HIV-1 has a decreased likelihood of being hypersusceptible to a protease inhibitor, comprising:
A method for determining whether an individual infected with HIV-1 has a decreased likelihood of being hypersusceptible to treatment with a protease inhibitor, comprising detecting, in a sample from said individual, the presence or absence of a mutation negatively associated with hypersusceptibility to treatment with said protease inhibitor at amino acid position 10, 15, 36, 41, 57, 60, 63, 71 or 93 of the amino acid sequence of the protease of the HIV-1, wherein the presence of said mutation indicates that the individual has a decreased likelihood of being hypersusceptible to treatment with the protease inhibitor.
Dependencies are inferred from the claim text.